John M. Evans, CEO at Beam Therapeutics Inc. (BEAM), sold 23,308 shares at $29.09 ($691K) on 2023-04-04, disclosed to the SEC on 2023-04-05.
Scheduled sale ($691k) by CEO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $30.31 | 5,161 | $156K | 22.7% |
| 2 | $30.31 | 5,161 | $156K | 22.7% |
| 3 | $29.09 | 6,493 | $189K | 27.3% |
| 4 | $29.09 | 6,493 | $189K | 27.3% |
| Total | $29.63 avg | 23,308 | $691K | 100% |
| Filing → |
| BEAM | SELL | 2026-04-01 | $1.1M | — | Filing → |
| BEAM | SELL | 2026-02-02 | $2.8M | — | Filing → |
| BEAM | SELL | 2025-10-03 | $1.2M | — | Filing → |